Drug Firms Model Ensuring Import Safety; China's Inconsistencies Worry FDA
This article was originally published in PharmAsia News
Executive Summary
Firms using Chinese imports to make dietary supplements and other products can look to drug firms for lessons on ensuring the safety of raw materials from China, where adherence to food and drug production regulations remains inconsistent, current and former FDA executives tell a Senate panel